The present invention pertains to methods and systems for automated regulatory-compliant assays. In particular, the present invention pertains, in part, to fully-automated methods and systems for conducting GMP-compliant cell-based bioassays.

The present invention pertains to methods and systems for automated regulatory-compliant assays. In particular, the present invention pertains, in part, to fully-automated methods and systems for conducting GMP-compliant cell-based bioassays.

Techniques for automatically measuring cell type based on electrical impedance includes single cell type or population cell types. Imaging a single cell includes measuring impedance time series while a single cell traverses a gap between a pair of electrodes in a microfluidic channel. A virtual image of the single cell is generated using a trained neural network and the measured impedance time series. Each training instance includes impedance time series of a training instance cell and a microscopic image of the cell. Automatically determining cell type of a population includes measuring population impedance time series while multiple cells of a sample traverse the gap. A measured probability density function (PDF) of amplitudes of isolated extrema in the population is generated. A first cell type in the sample is determined automatically based on the measured PDF and a database storing a PDF for each cell type of multiple cell types.

A genetic testing device 1 further comprises a calculation unit 2d that adds, to the time at which an analyte is put, an available standby time depending on the priority of the analyte and calculates a target time by which dispensation to the analyte is to be completed. A control unit 2c executes dispensation of analytes in the order of target time. Consequently, in the genetic testing method and genetic testing device provided by the present invention, priority is given to measurement of an analyte with high priority, and measurement of an analyte with low priority is prevented from being overly delayed when analytes with high priority are introduced in succession.